Abbott Laboratories ABT

Set alert

Price alert · ABT

All alert types
109.54 USD -0.62 -0.56%

As of Nov 3, 1:47 PM ET

Bid
109.53 × 1
Ask
109.56 × 1
109.09 Day range 110.60
82.56 52-week range 130.59
YTD
-12.57%
1 year
-11.55%
Open
109.36
Prev close
110.16
Mkt cap
190.86B
Vol
3.70M
Avg vol
8.77M
EPS
2.69
P/E
40.73
Div yield
2.41%
More statistics
Low
109.09
High
110.60
Forward P/E
18.57
Beta
0.54
Short ratio
1.84
Inst. own
81.92%
Dividend
2.52
Ex-div date
Oct 14, 2026
Earnings
Jan 28, 2027
50-d avg
104.34
200-d avg
101.69
1y target
118.52

15m chart

Chart tools
Interval

Built from the cached five-day intraday bars.

Signals (34)
NameTimeAgo
SMA: BearishNov 3, 12:55 PM52 minutes ago
SMA: BullishNov 3, 12:40 PM1 hour ago
SMA: BearishNov 3, 12:25 PM1 hour ago
SMA: BearishNov 3, 12:10 PM1 hour ago
SMA: BullishNov 3, 11:55 AM1 hour ago
SMA: BearishNov 3, 11:40 AM2 hours ago
SMA: BullishNov 3, 10:40 AM3 hours ago
SMA: BearishNov 3, 10:10 AM3 hours ago
SMA: BullishNov 3, 9:55 AM3 hours ago
SMA: BearishNov 3, 9:40 AM4 hours ago
SMA: BullishNov 2, 3:55 PM21 hours ago
SMA: BearishNov 2, 3:25 PM22 hours ago
MACD: Sell SignalNov 2, 2:40 PM23 hours ago
MACD: Buy SignalNov 2, 9:40 AM1 day ago
RSI: OverboughtNov 2, 9:40 AM1 day ago
SMA: BullishOct 30, 3:55 PM3 days ago
SMA: BearishOct 30, 3:25 PM3 days ago
SMA: BearishOct 30, 1:40 PM4 days ago
MACD: Sell SignalOct 30, 1:25 PM4 days ago
RSI: OverboughtOct 30, 12:25 PM4 days ago

Newest 20 of 34.

Key statistics

Market cap
192.07B
Enterprise value
211.54B
Trailing P/E
40.99
Forward P/E
18.57
PEG ratio
1.52
Price / sales
3.98
Price / book
3.73
EPS (TTM)
2.69
Beta
0.54
Dividend yield
2.37%
Payout ratio
78.71%
Profit margin
9.75%
Revenue (TTM)
48.23B
Revenue growth
14.50%
Free cash flow
0
Total cash
5.60B
Total debt
32.72B
Return on equity
0.00%
Shares outstanding
1.74B
Short % of float
1.12%
50-day average
104.34
200-day average
101.69

Financials — quick view

All financials
ABT Revenue — quarterly 12.59B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT Net income — quarterly 928.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT EPS — quarterly 0.53
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ABT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20261.64———
Oct 21, 2026Sep 30, 20261.421.420.000.00%
Jul 16, 2026Jun 30, 20261.281.31+0.03+2.34%
Apr 16, 2026Mar 31, 20261.141.15+0.01+0.88%
Jan 22, 2026Dec 31, 20251.501.500.000.00%
Oct 15, 2025Sep 30, 20251.301.300.000.00%

Upgrades / downgrades

ABT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026Argus ResearchdownBuyHold
Oct 23, 2026Wells FargomainOverweightOverweight
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 22, 2026Wells FargomainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
abbott.com

News

Your note

Sign in to keep a note on ABT — it syncs with the Stock Master app.

Insider holders

ABT insider holders
InsiderRelationLatest transactionDateShares held
ALLEN HUBERT L.OfficerStock Award(Grant)Feb 24, 2025200,281
BOUDREAU PHILIP PChief Financial OfficerPurchaseApr 22, 20260
CONROY KEVIN TDirectorStock Award(Grant)Apr 23, 2026133,737
EARNHARDT LISA DOfficerStock Award(Grant)Feb 23, 202698,984
FORD ROBERT B.Chief Executive OfficerSaleAug 24, 2026522,664
MORELAND MARY KOfficerSaleMar 1, 2026116,136

Institution ownership

ABT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.82%152,563,47616.82BJun 29, 2026
Vanguard Capital Management LLC6.57%113,750,99412.54BJun 29, 2026
State Street Corporation4.68%80,926,2348.92BJun 29, 2026
Charles Schwab Investment Management, Inc.3.45%59,674,5076.58BJun 29, 2026
Vanguard Portfolio Management LLC2.83%49,017,8665.41BJun 29, 2026
Geode Capital Management, LLC2.27%39,219,3374.32BJun 29, 2026

Fund ownership

ABT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.20%55,297,2796.10BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF2.75%47,631,7455.25BAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%45,138,4904.98BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%23,056,9072.54BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.31%22,610,2902.49BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%21,408,9182.36BSep 29, 2026